Answers are grounded in this paper and cite their sources.
BACKGROUND: Although classic psychedelic trials show therapeutic potential, the limited diversity of participants raises concerns about generalizability and safety. AIMS: This study assesses the representation of race, ethnicity, and sex in interventional clinical trials of psilocybin and lysergic acid diethylamide (LSD) to evaluate disparities in participant diversity. METHODS: We conducted a cross-sectional analysis of interventional trials registered on ClinicalTrials.gov up to 12 January 2025 that focused on classic psychedelics (psilocybin, psilocin, LSD, DMT, 5-MeO-DMT, and mescaline). Eligible trials were phases 2-4 and targeted psychiatric disorders or symptoms. Trials involving only healthy participants were excluded. Two reviewers extracted trial-level data independently; discrepancies were resolved by consensus. RESULTS: = 11) included older adults (average age: 51.7 years) who did not provide any information on race or origin. CONCLUSIONS: The limited diversity in psychedelic trials demonstrates the need for broader recruitment. Without better representation, the safety and efficacy of these therapies remain uncertain. Standardized reporting and targeted strategies are essential to ensure equity.
No takes yet. Share an insight, caveat, or question.
Świeczkowski et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: